Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2566 to 2580 of 8904 results

  1. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]

    Awaiting development Reference number: GID-TA11403 Expected publication date: TBC

  2. d-NAV for optimization of personal insulin management in adults with type 2 diabetes (MT696)

    Topic prioritisation

  3. COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment

    In development Reference number: GID-HTE10011 Expected publication date: TBC

  4. Digital technologies to support self-management of asthma: early value assessment

    In development Reference number: GID-HTE10063 Expected publication date:  30 April 2026

  5. PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [ID1439]

    Awaiting development Reference number: GID-TA11325 Expected publication date: TBC

  6. Upadacitinib for treating giant cell arteritis [ID6299]

    In development Reference number: GID-TA11330 Expected publication date: TBC

  7. Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain

    Awaiting development Reference number: GID-HTG10168 Expected publication date: TBC

  8. Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]

    In development Reference number: GID-TA11058 Expected publication date: TBC

  9. Plozasiran for treating familial chylomicronaemia syndrome [ID6593]

    In development Reference number: GID-TA11793 Expected publication date:  18 November 2026

  10. Ectopic pregnancy and miscarriage: diagnosis and initial management (update)

    In development Reference number: GID-NG10444 Expected publication date:  06 May 2026

  11. Ectopic pregnancy and miscarriage: diagnosis and initial management (update): draft guidance consultation

    We are listening to your views on this NICE guideline. Comments close 17 February 2026.

  12. Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [ID1259]

    In development Reference number: GID-TA10225 Expected publication date: TBC

  13. Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]

    In development Reference number: GID-TA11130 Expected publication date: TBC

  14. Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years [ID3897]

    In development Reference number: GID-TA11437 Expected publication date: TBC

  15. Asunercept for treating glioblastoma [ID1301]

    In development Reference number: GID-TA10227 Expected publication date: TBC